Top Markets
#1 Islamic Coin Islamic Coin +151.47%
#2 DOVU DOVU +48.45%
#3 Black Phoenix Black Phoenix +34.85%
#4 Velvet Velvet +30.94%
#5 Cross Cross +19.36%
#6 Akedo Akedo +17.98%
#7 DoubleZero DoubleZero +14.50%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.43%
#9 Fake World Assets Fake World Assets +10.49%
#10 Cap Cap +10.24%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Vincerx Pharma, Inc. Vincerx Pharma, Inc.

Vincerx Pharma, Inc.

VINC
Kedudukan dalam Saham #40887
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical... Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Harga Saham
$0.0127
Disegerakkan terakhir: 2026-08-12
Modal Pasaran
$66.48K
Perubahan (1 hari)
-2.31%
Perubahan (1 tahun)
-67.44%
Negara
US
Perdagangan Vincerx Pharma, Inc. (VINC)

Kategori

Healthcare
Hasil untuk Vincerx Pharma, Inc. (VINC)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Vincerx Pharma, Inc., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Vincerx Pharma, Inc. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE